At a glance
Selected evidence now includes ageing mice, the negative MMPOWER-3 human myopathy trial, and controlled and open-label Barth syndrome studies. Disease biology, endpoints and study designs differ; longer uncontrolled improvement cannot be interpreted as if it came from the randomised comparison.
Identity & scope
Elamipretide is the mitochondria-targeting peptide also called SS-31 in the cited research. A shared compound name does not establish equivalence between clinical-trial material and a supplier vial or nasal formulation.
What the research shows
- Nickel and colleagues found sex-dependent functional changes in ageing mice, including different physical and cognitive findings.
- MMPOWER-3 did not improve its primary walking-distance or fatigue outcomes in people with genetically confirmed primary mitochondrial myopathy.
Critical interpretation
Keep the controlled and extension phases separate
The most informative comparison for a causal treatment effect is the prespecified contrast between randomised groups or periods. The Barth study illustrates why an encouraging extension should not be retrospectively substituted for that comparison. Longer follow-up can reveal durability or delayed signals, but all participants then know they receive treatment and the original control structure has gone. The extension is also the same cohort, so citing both reports is not evidence from two independent populations. [3] [4]
A null endpoint has a defined scope
MMPOWER-3 constrains claims about the walking and fatigue outcomes it actually tested. It does not prove that every mitochondrial mechanism is inactive, and it does not license selecting a favourable exploratory subgroup as a confirmed success. A credible next study would specify the subgroup and endpoint prospectively, define a meaningful effect size and replicate it. For researchers, trial duration, molecular diagnosis and formulation are therefore central study characteristics rather than footnotes. [2]
Translation is not chemical identity
The mouse findings motivate questions about function and sex-specific responses. They cannot bridge the separate analytical question of whether a marketed vial or nasal preparation matches clinical study material. Procurement and biological evidence need their own documentation. [1] [3]
Limitations & uncertainties
- A mouse functional outcome is not evidence of longer human lifespan.
- A disease-specific pharmaceutical trial cannot be treated as proof for general wellness, muscle growth or a different supplied format.
- This review does not assess regulatory approval or authenticate HeartPep batches.
Open research questions
- Which clinical populations and prespecified outcomes can show a reproducible benefit?
- How do actual formulation, identity and exposure compare with the study material?
Selected papers & source records
Download bibliography1. Long-term treatment with Elamipretide enhances healthy aging phenotypes in mice (opens in a new tab)
Nickel K, Zhu L, Mangalindan R, et al. (2022). Aging Pathobiology and Therapeutics. DOI: 10.31491/apt.2022.09.089 (opens in a new tab) · PMID 36250163
- Design & population
- Long-term treatment of male and female C57BL/6 mice starting at 18 months, with physiological assessment at 28 months.
- What the study found
- Physical performance improved in males but not females; cognitive and body-composition findings differed by sex. Diastolic function improved in both sexes.
- Limits on interpretation
- Specific mouse functional endpoints, not a human longevity study. Effects varied by sex and context.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
2. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial (opens in a new tab)
Karaa A, Bertini E, Carelli V, et al.; MMPOWER-3 Trial Investigators (2023). Neurology. DOI: 10.1212/WNL.0000000000207402 (opens in a new tab) · PMID 37268435
- Design & population
- Phase 3 double-blind placebo-controlled trial in 218 people with genetically confirmed primary mitochondrial myopathy over 24 weeks.
- What the study found
- Neither primary endpoint, six-minute walking distance nor total fatigue score, improved significantly versus placebo.
- Limits on interpretation
- Clinical formulation and disease-specific setting. The null primary results should not be replaced with selected exploratory subgroup findings.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
3. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism (opens in a new tab)
Thompson WR, Hornby B, Manuel R, et al. (2021). Genetics in Medicine. DOI: 10.1038/s41436-020-01006-8 (opens in a new tab) · PMID 33077895
- Design & population
- Single-site double-blind placebo-controlled crossover trial in 12 males with genetically confirmed Barth syndrome, followed by an open-label extension.
- What the study found
- Neither primary endpoint improved significantly in the controlled phase. Improvements were reported during the subsequent open-label phase.
- Limits on interpretation
- Very small rare-disease sample. Open-label within-person changes have no concurrent placebo control; sponsor participated in analysis and publication.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
4. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER (opens in a new tab)
Thompson WR, Manuel R, Abbruscato A, et al. (2024). Genetics in Medicine. DOI: 10.1016/j.gim.2024.101138 (opens in a new tab) · PMID 38602181
- Design & population
- Long-term open-label follow-up of TAZPOWER; ten participants entered and eight reached week 168.
- What the study found
- Reported sustained within-person functional and selected cardiac improvements, with injection-site reactions the most common adverse events.
- Limits on interpretation
- Same underlying cohort rather than independent replication. No randomised long-term comparator; attrition and expectation effects complicate causal attribution.
Search & review scope
Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.. Checked 9 November 2026.
Mouse ageing, phase 3 myopathy, and small Barth syndrome controlled/open-label evidence. Full-text trial methods were consulted where accessible. Regulatory status and catalogue-product approval were not assessed.
Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates.
Recorded search terms
- 36250163 elamipretide long term aging mice
- elamipretide MMPOWER-3 randomized trial primary mitochondrial myopathy 2023
- "MMPOWER-3" "Karaa" "10." 2023
- elamipretide Barth syndrome TAZPOWER trial randomized crossover 2021 PubMed
- elamipretide Barth syndrome 168 weeks open label 2025 primary trial
- "10.1212/WNL.0000000000207402" correction
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. SS-31 (elamipretide): literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/ss-31.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.